Quality of intubation using remifentanil in obese patients (OBEREM): A randomised, double-blind pilot trial
Authors' conclusion
An NMBA-free induction sequence with remifentanil may be feasible in obese patients, providing acceptable, easy, and atraumatic intubating conditions. Increasing the remifentanil dose does not appear to significantly improve these conditions.
Study context
- Population
- Obese patients undergoing bariatric surgery
- Comparison
- Remifentanil 3 µg kg-1 + 30% vs 3 µg kg-1, both with propofol
- Primary endpoint
- Percentage of patients with excellent intubation conditions
Methodological detailspilot, prospective, single-centre, double-blind
- Pilot
- Prospective
- Single-centre
- Double-blind
Primary result
As reported in the abstract
Excellent intubation conditions
Excellent intubation conditions, all patients
32.8%
Acceptable (excellent or good) intubation conditions, all patients
86.2%
Secondary outcomes
Intubation difficulty
- Intubation rated easy, all patients
- 89.7%
Safety
- Serious complications
- 0
- Arterial hypotension
- 93.1%
- Bradycardia
- 48.3%
- Haemodynamic instability frequent
Original publication
Quality of intubation using remifentanil in obese patients (OBEREM): A randomised, double-blind pilot trial. Anaesth Crit Care Pain Med. Published 7 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →